WGS — GeneDx Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $4.83bn
- $4.72bn
- $305.45m
Annual cashflow statement for GeneDx Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -241 | -245 | -549 | -176 | -52.3 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 123 | 25.1 | -24.4 | 1.05 | 26.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 13.8 | 8.08 | 195 | -39.2 | -24.7 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -93.1 | -190 | -319 | -180 | -28.5 |
| Capital Expenditures | -32 | -20.8 | -14.3 | -5.71 | -5.49 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | 0 | — | -127 | -38 | -24.6 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -32 | -20.8 | -141 | -43.7 | -30.1 |
| Financing Cash Flow Items | 0 | 506 | 198 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 129 | 494 | 197 | 186 | 44.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.95 | 283 | -263 | -37.6 | -14.5 |